Targeted therapy for melanoma: rational combinatorial approaches.
作者： L N Kwong , M A Davies
DOI: 10.1038/ONC.2013.34
关键词:
摘要: The treatment of melanoma, the most aggressive form skin cancer, is being revolutionized by development personalized targeted therapy approaches. Mutant-selective BRAF inhibitors and MEK have demonstrated impressive clinical results in molecularly selected patients. However, emerging understanding molecular heterogeneity this disease identification multiple mechanisms resistance to therapies strongly support rationale for combinatorial In review, we will discuss preclinical studies that are testing leading hypotheses strategies future.
nature.com
sci-hub.se 参考文章(85)
Fritz Lai, Lei Jin, Stuart Gallagher, Branka Mijatov, Xu Dong Zhang, Peter Hersey, None, Histone Deacetylases (HDACs) as Mediators of Resistance to Apoptosis in Melanoma and as Targets for Combination Therapy with Selective BRAF Inhibitors Advances in Pharmacology. ,vol. 65, pp. 27- 43 ,(2012) , 10.1016/B978-0-12-397927-8.00002-6
Bianca Devitt, Wendy Liu, Renato Salemi, Rory Wolfe, John Kelly, Chin-Yuan Tzen, Alexander Dobrovic, Grant McArthur, Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma Pigment Cell & Melanoma Research. ,vol. 24, pp. 666- 672 ,(2011) , 10.1111/J.1755-148X.2011.00873.X
Ruth Halaban, Wengeng Zhang, Antonella Bacchiocchi, Elaine Cheng, Fabio Parisi, Stephan Ariyan, Michael Krauthammer, James P McCusker, Yuval Kluger, Mario Sznol, None, PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells Pigment Cell & Melanoma Research. ,vol. 23, pp. 190- 200 ,(2010) , 10.1111/J.1755-148X.2010.00685.X
Pablo Rodriguez-Viciana, Patricia H. Warne, Ritu Dhand, Bart Vanhaesebroeck, Ivan Gout, Michael J. Fry, Michael D. Waterfield, Julian Downward, PHOSPHATIDYLINOSITOL-3-OH KINASE AS A DIRECT TARGET OF RAS Nature. ,vol. 370, pp. 527- 532 ,(1994) , 10.1038/370527A0
W. Deng, Y. N. Vashisht Gopal, A. Scott, G. Chen, S. E. Woodman, M. A. Davies, Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell & Melanoma Research. ,vol. 25, pp. 248- 258 ,(2012) , 10.1111/J.1755-148X.2011.00950.X
Giao Q. Phan, Peter Attia, Seth M. Steinberg, Donald E. White, Steven A. Rosenberg, Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. Journal of Clinical Oncology. ,vol. 19, pp. 3477- 3482 ,(2001) , 10.1200/JCO.2001.19.15.3477
Michael B. Atkins, Michael T. Lotze, Janice P. Dutcher, Richard I. Fisher, Geoffrey Weiss, Kim Margolin, Jeff Abrams, Mario Sznol, David Parkinson, Michael Hawkins, Carolyn Paradise, Lori Kunkel, Steven A. Rosenberg, High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993 Journal of Clinical Oncology. ,vol. 17, pp. 2105- 2116 ,(1999) , 10.1200/JCO.1999.17.7.2105
Vanessa S. Rodrik-Outmezguine, Sarat Chandarlapaty, Nen C. Pagano, Poulikos I. Poulikakos, Maurizio Scaltriti, Elizabeth Moskatel, José Baselga, Sylvie Guichard, Neal Rosen, mTOR Kinase Inhibition Causes Feedback-Dependent Biphasic Regulation of AKT Signaling Cancer Discovery. ,vol. 1, pp. 248- 259 ,(2011) , 10.1158/2159-8290.CD-11-0085
Lawrence N Kwong, James C Costello, Huiyun Liu, Shan Jiang, Timothy L Helms, Aliete E Langsdorf, David Jakubosky, Giannicola Genovese, Florian L Muller, Joseph H Jeong, Ryan P Bender, Gerald C Chu, Keith T Flaherty, Jennifer A Wargo, James J Collins, Lynda Chin, Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma Nature Medicine. ,vol. 18, pp. 1503- 1510 ,(2012) , 10.1038/NM.2941
David Dankort, David P Curley, Robert A Cartlidge, Betsy Nelson, Anthony N Karnezis, William E Damsky Jr, Mingjian J You, Ronald A DePinho, Martin McMahon, Marcus Bosenberg, BrafV600E cooperates with Pten loss to induce metastatic melanoma Nature Genetics. ,vol. 41, pp. 544- 552 ,(2009) , 10.1038/NG.356